In this Issue

• Largest LSD Microdosing Trial to Date Fails Across All Endpoints
• AtaiBeckley’s Phase 2b Debrief: More Detail on SAE and Phase 3 Considerations
• UK Government Holds Line on Psilocybin Despite New Cross-Party Written Questions
• MAHA Summit Features Psychedelics
• VA Reveals Phase 3 Psilocybin Study
• Other Stories

***

Largest LSD Microdosing Trial to Date Fails Across All Endpoints

Last Issue, we reported the publication of a small (N=19), open-label trial of LSD microdosing for major depressive disorder (MDD) that saw a 59.5% reduction in MADRS scores, which the authors said was sustained for up to six months. The Phase 2b results from the same program, sponsored by MindBio, were forthcoming.

Well, now we have a topline readout from that Phase 2b (N=89) study, which came by way of a LinkedIn post from the company’s CEO and co-founder, Justin Hanka, as well as an email newsletter.

“Surprised, Disappointed”, the email opens, with the CEO writing that he is “disappointed to discover that microdosing [LSD] is not effective, compared to placebo[,] in changing depression scores using the global standard MADRS”.

“[W]ith a good level of certainty…microdosing LSD is not effective at treating patients with Major Depressive Disorder in placebo controlled trials”, Hanka wrote. He described it as “[a]n incredibly surprising result”, hinting at just how irredeemable it is.

Indeed, speaking to Psychedelic Alpha, Hanka confirmed that “none of the primary or secondary endpoints were met, when compared to placebo in this trial.”

To continue reading this Issue of the Psychedelic Bulletin, please sign in or join Pα+ today…